Bruce I Sachs bought $1.9M of Vertex Pharmaceuticals Incorporated (VRTX)
Executed Aug 6 2025, disclosed Aug 7 2025, 1 day later.
Over the 21 trading sessions from the disclosed entry session (Aug 7 2025), the stock returned +2.9% (delay-adjusted); from the execution session (Aug 6 2025), +5.6%. Derived: entry at the session's open, exit at the close 20 sessions later.
Bruce I Sachs (Director) filed 1 Form 4 report in the past 24 months (1 purchase, 0 sales), most often in Vertex Pharmaceuticals Incorporated (VRTX). Across 1 priced purchase filing, the average 21-session return was +5.6% from execution and +2.9% from disclosure (delay-adjusted; derived). The largest single filing was $1.9M of VRTX (5,000 sh across 2 lots, as filed), executed Aug 6 2025.
Healthcare · Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→